TL;DR
The race for cardiometabolic dominance is fracturing along clinical and legal fault lines as developers look beyond traditional subcutaneous GLP-1 therapies. While Novo Nordisk faced a major setback in its non-GLP-1 cardiovascular pipeline, competitors like Viking and Kailera are aggressively pushing forward with oral formulations, utilizing both clinical acceleration and international patent litigation to challenge the status quo.
The Fragility of Cardiometabolic Diversification
The quest to diversify beyond pure GLP-1 receptor agonists is hitting severe scientific roadblocks, raising questions about the validity of non-GLP-1 cardiovascular targets.
"Although ziltivekimab produced the expected biological effect, this did not result in MACE benefits in this population. While ziltivekimab did not achieve the MACE benefit we had hoped for, this does not change our strategic commitment to cardiovascular disease." — Martin Holst Lange, MD, PhD, Executive Vice President and Head of R&D at Novo Nordisk via novo-nordisk-cardiovascular-pipeline-ziltivekimab
This failure in the Phase III ZEUS trial underscores that biomarker engagement—specifically lowering systemic inflammation markers like hsCRP—does not automatically translate to clinical cardiovascular protection novo-nordisk-cardiovascular-pipeline-ziltivekimab. The immediate stock market collapse of other biotechs targeting this pathway shows how heavily the industry has bet on these mechanisms novo-nordisk-cardiovascular-pipeline-ziltivekimab
.
What to watch: Watch whether Novo Nordisk can salvage the program in its upcoming HERMES and ARTEMIS Phase III trials expected to read out in 2027 novo-nordisk-cardiovascular-pipeline-ziltivekimab.
The High-Stakes Battle for Oral GLP-1 Dominance
The commercial race for daily oral weight-loss therapies is transitioning from clinical validation to aggressive intellectual property disputes and rapid corporate scaling.
"Dorothy joins our Board as Viking advances its next-generation therapies, prepares for VK2735's potential launch, and strengthens our commercialization capabilities." — Brian Lian, Ph.D., CEO of Viking Therapeutics via viking-therapeutics-oral-vk2735-phase-2-venture
As Viking positions itself to launch the first oral dual GLP-1/GIP agonist with a planned Phase 3 start, competitors are using legal maneuvers to clear their paths, as seen in Kailera’s aggressive Section 1782 discovery action targeting Structure’s oral dosing patents viking-therapeutics-oral-vk2735-phase-2-venture[oral-glp1-patent-litigation-kailera-structure](/topics/019e84f3-e46c-7c64-bcce-6d0ef82f7c3f/notes/oral-glp1-patent-litigation-kailera-structure]. These maneuvers show that securing market share for oral formulations requires both regulatory speed and defensive legal moats oral-glp1-patent-litigation-kailera-structure
.
What to watch: Watch whether the California federal court grants Kailera's discovery request to force Structure to release its internal R&D documents oral-glp1-patent-litigation-kailera-structure.
Corporate Financial Overhangs in the GLP-1 Era
Even as the GLP-1 market promises historic windfalls, legacy financial and tax liabilities continue to constrain the balance sheets of key developers.
"Amgen reached a $74 million settlement of a lawsuit accusing the biotechnology company of waiting too long to disclose that it might owe the IRS $10.7 billion..." — Reuters Article via amgen-irs-tax-dispute-shareholder-settlement
Amgen's willingness to settle the shareholder suit for millions shows a desire to clean up disclosure issues, yet the true financial shadow is the looming transfer pricing decision that could severely drain cash reserves just as the company tries to scale its pipeline amgen-irs-tax-dispute-shareholder-settlement.
What to watch: Watch for the U.S. Tax Court's final ruling on the transfer pricing dispute, expected by the end of 2026 amgen-irs-tax-dispute-shareholder-settlement.
What surprised us
- Biomarker Success, Clinical Failure: It is highly surprising that ziltivekimab successfully achieved significant reductions in systemic inflammatory biomarkers (free IL-6 and hsCRP) but yielded virtually zero clinical benefit in preventing actual cardiovascular deaths, heart attacks, or strokes novo-nordisk-cardiovascular-pipeline-ziltivekimab
.
- Kailera's Bold Legal Offensive: Rather than fighting solely in European patent offices, newly public Kailera is leveraging U.S. federal courts to force Structure to hand over internal R&D documents, showing a highly aggressive legal strategy early in its public life oral-glp1-patent-litigation-kailera-structure
.
- Viking's Commercial Pivot: Viking is moving rapidly from an R&D biotech to a commercial-ready pharmaceutical competitor, appointing commercial executive Dorothy Gemmell to its board as it readies its oral dual GLP-1/GIP agonist for Phase 3 viking-therapeutics-oral-vk2735-phase-2-venture
.
Open threads worth a vote
[watch] Amgen Q2 2026 Earnings Release](/topics/019e84f3-e46c-7c64-bcce-6d0ef82f7c3f#threads)[watch] Structure Therapeutics Q2 2026 Earnings Release](/topics/019e84f3-e46c-7c64-bcce-6d0ef82f7c3f#threads)